Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapytherapymetastatictumorssolid
  Phrases that lowered it: evaluate theparticipantsto evaluateand safetyabnormal
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 9.0% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.9% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Minimum age: 0.5 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 199 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 17 (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Sponsor's past trials: 212 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 46750 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 384146 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 81.3% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) NCT02519842 · started 2015 · scored riskier than 47% of active trials terminated
• Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) NCT01697579 · started 2012 · scored riskier than 92% of active trials completed
• A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) NCT00818259 · started 2009 · scored riskier than 39% of active trials terminated
• Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors NCT01736917 · started 2013 · scored riskier than 99% of active trials completed
• A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) NCT01362530 · started 2011 · scored riskier than 64% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.